TY  - GEN
AU  - Papadopoulos,Kyriakos P
AU  - Tabernero,Josep
AU  - Markman,Ben
AU  - Patnaik,Amita
AU  - Tolcher,Anthony W
AU  - Baselga,José
AU  - Shi,Weiliang
AU  - Egile,Coumaran
AU  - Ruiz-Soto,Rodrigo
AU  - Laird,A Douglas
AU  - Miles,Dale
AU  - Lorusso,Patricia M
TI  - Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors
SN  - 1557-3265
PY  - 2015///0820
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - pharmacology
KW  - Drug Monitoring
KW  - Female
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Neoplasms
KW  - drug therapy
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Quinoxalines
KW  - Signal Transduction
KW  - drug effects
KW  - Sulfonamides
KW  - TOR Serine-Threonine Kinases
KW  - antagonists & inhibitors
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-13-2403
ER  -